基线基底细胞增生与重复活检中基线下尿路症状、临床前列腺炎或前列腺癌无关
该回顾性分析纳入6471名50-75岁、PSA 2.5-10 ng/ml且既往活检阴性的男性,评估基线基底细胞增生(BCH)与下尿路症状(LUTS)/良性前列腺增生(BPH)、临床前列腺炎及未来前列腺癌的关系。结果显示BCH与更少慢性炎症和更多前列腺萎缩相关(P<0.05),但与重复活检前列腺癌、BPH/LUTS或临床前列腺炎均无关联。
要点
- 基线BCH与更少慢性炎症和更多前列腺萎缩相关(P<0.05)。
- BCH与重复活检前列腺癌风险无关(多因素OR=1.15,95%CI 0.61-2.16)。
- BCH与BPH/LUTS及临床前列腺炎均无关联。
核心结论
- 在基线活检阴性并接受重复前列腺活检的男性中,BCH与更多组织学萎缩和更少慢性前列腺炎相关,但与LUTS/BPH、临床前列腺炎或未来前列腺癌风险无关。
研究设计与样本
- 回顾性分析纳入6471名50-75岁、前列腺特异性抗原2.5-10 ng/ml且既往活检阴性的男性,均来自Reduce by Dutasteride of PCa Events试验并接受2年重复活检。
主要发现
- 6471名入组男性中,84名(1.3%)基线前列腺活检存在BCH。
- BCH与更少慢性炎症和更多前列腺萎缩相关(P<0.05),且与基线患者特征无关。
- 单因素分析中BCH与重复活检前列腺癌无关(OR=0.98,95%CI 0.53-1.82,P>0.05),多因素分析亦无关(OR=1.15,95%CI 0.61-2.16,P>0.05)。
- 单因素分析中BCH与BPH/LUTS无关(OR=1.13,95%CI 0.71-1.81,P>0.05),多因素分析亦无关(OR=1.20,95%CI 0.74-1.94,P>0.05)。
- 单因素分析中BCH与临床前列腺炎无关(OR=0.56,95%CI 0.18-1.81,P>0.05),多因素分析亦无关(OR=0.57,95%CI 0.18-1.83,P>0.05)。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To evaluate whether the presence of basal cell hyperplasia (BCH) in negative biopsies is associated with concurrent lower urinary tract symptoms (LUTS) and benign prostatic hyperplasia (BPH), clinical prostatitis, and future prostate cancer (PCa) in repeat prostate biopsy. METHODS: We performed a retrospective analysis of 6471 men, 50-75 years old with prostate-specific antigen between 2.5 and 10 ng/ml and prior negative biopsy who were enrolled in the Reduction by Dutasteride of PCa Events trial and underwent a 2-year repeat biopsy. The association between baseline BCH and risk of PCa, BPH/LUTS and clinical prostatitis measured at baseline were evaluated with logistic regression in uni/multivariable analysis, controlling for baseline patient characteristics. RESULTS: Among 6471 men enrolled, 84 (1.3%) had BCH in the baseline prostate biopsy. BCH was associated less chronic inflammation and more prostate atrophy (P < 0.05) and was unrelated to baseline patient characteristics. In both uni/multivariable analyses, BCH was not associated with PCa in repeat biopsy (univariable odds ratio [OR] = 0.98, 95% confidence interval [CI] = 0.53-1.82, P > 0.05; multivariable OR=1.15, 95% CI = 0.61-2.16, P > 0.05), BPH/LUTS (univariable OR = 1.13, 95% CI = 0.71-1.81, P > 0.05; multivariable OR = 1.20, 95% CI = 0.74-1.94, P > 0.05), or clinical prostatitis (univariable OR = 0.56, 95% CI = 0.18-1.81, P > 0.05; multivariable OR = 0.57, 95% CI = 0.18-1.83, P > 0.05). CONCLUSION: Among men undergoing repeat prostate biopsy with a baseline negative biopsy, BCH was associated with more histological atrophy and less chronic prostatitis, but was unrelated to LUTS/BPH, clinical prostatitis or future PCa risk.
引用
- Freitas D, Andriole GL, Freedland SJ, et al. Baseline Basal Cell Hyperplasia Is not Associated With Baseline Lower Urinary Tract Symptoms, Baseline Clinical Prostatitis or Prostate Cancer in Repeat Biopsies. Urology. 2019. PMID: 30914334. doi:10.1016/j.urology.2019.02.034
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。